



## IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

16 December 2020

### First-in-human study update: Study open for enrolment

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense™ HER2 breast cancer Phase I first-in-human study.

Dr Jane Fox, the current Director of Breast Services at Monash Health, which encompasses breast surgery and the Monash BreastScreen program, has been named as the Principal Investigator of the MagSense™ study. Dr Fox is also a senior lecturer in the Monash University Department of Surgery and a senior leader of the multi-disciplinary team at the Monash Cancer Centre which includes medical imaging, medical oncology and radiation oncology.

Bob Proulx, Executive Chairman of Imagion Biosystems said, "We are delighted to be working with a leading healthcare organization and with Dr. Jane Fox, a highly regarded clinician who has dedicated her career to improving outcomes for patients with breast cancer and who is strongly supportive of the trial. After all the diligence and hard work, it is extremely exciting to be initiating our first clinical study."

**-ENDS**

#### About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

#### Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

#### U.S. Media Contact:

Matthew Wygant  
[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)  
+1-408-905-7630

#### Australian Media & Investor Relations:

Kyahn Williamson, WE Communications  
[We-AUImagionBiosystems@we-worldwide.com](mailto:We-AUImagionBiosystems@we-worldwide.com)  
+61 (0) 401018828

**Imagion Biosystems Limited**

ACN 616 305 027  
Level 25, 525 Collins Street, Melbourne VIC 3000  
[www.imagionbiosystems.com](http://www.imagionbiosystems.com)